BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

776 related articles for article (PubMed ID: 21704448)

  • 1. ICUD-EAU International Consultation on Kidney Cancer 2010: treatment of metastatic disease.
    Patard JJ; Pignot G; Escudier B; Eisen T; Bex A; Sternberg C; Rini B; Roigas J; Choueiri T; Bukowski R; Motzer R; Kirkali Z; Mulders P; Bellmunt J
    Eur Urol; 2011 Oct; 60(4):684-90. PubMed ID: 21704448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EORTC-GU group expert opinion on metastatic renal cell cancer.
    de Reijke TM; Bellmunt J; van Poppel H; Marreaud S; Aapro M
    Eur J Cancer; 2009 Mar; 45(5):765-73. PubMed ID: 19157861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic therapy for metastatic renal cell carcinoma in treatment naïve patients: a risk-based approach.
    Bukowski RM
    Expert Opin Pharmacother; 2010 Oct; 11(14):2351-62. PubMed ID: 20586712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of anti-angiogenic treatments on metastatic renal cell carcinoma.
    Ainsworth NL; Lee JS; Eisen T
    Expert Rev Anticancer Ther; 2009 Dec; 9(12):1793-805. PubMed ID: 19954291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New treatment approaches in renal cell carcinoma.
    Facchini G; Perri F; Caraglia M; Pisano C; Striano S; Marra L; Fiore F; Aprea P; Pignata S; Iaffaioli RV
    Anticancer Drugs; 2009 Nov; 20(10):893-900. PubMed ID: 19752718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted therapy in the treatment of metastatic renal cell cancer.
    Di Lorenzo G; Scagliarini S; Di Napoli M; Scognamiglio F; Rizzo M; Carteni' G
    Oncology; 2009; 77 Suppl 1():122-31. PubMed ID: 20130440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequential therapy with targeted agents in patients with advanced renal cell carcinoma: optimizing patient benefit.
    Oudard S; Elaidi RT
    Cancer Treat Rev; 2012 Dec; 38(8):981-7. PubMed ID: 22289686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel targeted therapy for advanced renal carcinoma: trials in progress.
    Calabrò F; Sternberg CN
    Curr Opin Urol; 2010 Sep; 20(5):382-7. PubMed ID: 20625300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new patient-focused approach to the treatment of metastatic renal cell carcinoma: establishing customized treatment options.
    Bellmunt J; Eisen T; Szczylik C; Mulders P; Porta C
    BJU Int; 2011 Apr; 107(8):1190-9. PubMed ID: 21078050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current systemic management of metastatic renal cell carcinoma - first line and second line therapy.
    Wright I; Kapoor A
    Curr Opin Support Palliat Care; 2011 Sep; 5(3):211-21. PubMed ID: 21725244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Second-line systemic therapy for the treatment of metastatic renal cell cancer.
    Kruck S; Bedke J; Kuczyk MA; Merseburger AS
    Expert Rev Anticancer Ther; 2012 Jun; 12(6):777-85. PubMed ID: 22716494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascular endothelial growth factor and mTOR pathways in renal cell carcinoma: differences and synergies of two targeted mechanisms.
    Mulders P
    BJU Int; 2009 Dec; 104(11):1585-9. PubMed ID: 20053190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on the medical treatment of metastatic renal cell carcinoma.
    Ravaud A; Wallerand H; Culine S; Bernhard JC; Fergelot P; Bensalah K; Patard JJ
    Eur Urol; 2008 Aug; 54(2):315-25. PubMed ID: 18485581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improving outcomes in patients with advanced renal cell carcinoma.
    Sosman JA
    Expert Rev Anticancer Ther; 2008 Mar; 8(3):481-90. PubMed ID: 18366295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of patients with metastatic renal cell cancer: a RAND Appropriateness Panel.
    Halbert RJ; Figlin RA; Atkins MB; Bernal M; Hutson TE; Uzzo RG; Bukowski RM; Khan KD; Wood CG; Dubois RW
    Cancer; 2006 Nov; 107(10):2375-83. PubMed ID: 17048248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The therapy of kidney cancer with biomolecular drugs.
    Di Lorenzo G; Buonerba C; Biglietto M; Scognamiglio F; Chiurazzi B; Riccardi F; Cartenì G
    Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S16-20. PubMed ID: 21129605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted Therapy for Metastatic Renal Cell Carcinoma.
    Afriansyah A; Hamid AR; Mochtar CA; Umbas R
    Acta Med Indones; 2016 Oct; 48(4):335-347. PubMed ID: 28143997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.
    Chan HY; Grossman AB; Bukowski RM
    Adv Ther; 2010 Aug; 27(8):495-511. PubMed ID: 20623346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted therapy of renal cell cancer.
    Wysocki PJ; Zolnierek J; Szczylik C; Mackiewicz A
    Curr Opin Investig Drugs; 2008 Jun; 9(6):570-5. PubMed ID: 18516756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Role of surgery (cytoreductive nephrectomy and metastasectomy) in the management of metastatic renal cell carcinoma: a literature review].
    Arroua F; Maurin C; Carcenac A; Ragni E; Rossi D; Bastide C
    Prog Urol; 2010 Dec; 20(13):1175-83. PubMed ID: 21130395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.